Idarubicinol Myelotoxicity in High-Dose Chemotherapy
Author Information
Author(s): Corsini C, Ghielmini M, Mancuso P, Tealdo F, Paolucci M, Zucchetti M, Ferrucci P F, Cocorocchio E, Mezzetti M, Mori A, Riggi M, D'Incalci M, Martinelli G
Primary Institution: European Institute of Oncology
Hypothesis
Does idarubicinol in patients' plasma affect the inhibition of infused progenitors during high-dose idarubicin treatment?
Conclusion
Plasma drug concentration on the day of stem cell reinfusion may overestimate the toxicity of residual anthracyclines to the transplanted cells.
Supporting Evidence
- Idarubicinol was evaluated for its toxicity on haematopoietic progenitors.
- Colony inhibition was correlated with pharmacokinetic data and engraftment time.
- Plasma samples before treatment showed a 72% increase in cloning efficiency.
- The inhibitory effect of patients' plasma on CFU-GM was lower than expected.
- Recovery of WBC and PLT correlated with the amount of CD34+ cells reinfused.
Takeaway
This study looked at how a cancer drug affects blood cell growth in patients. It found that the drug's presence might not be as harmful as expected.
Methodology
The study evaluated the toxicity of idarubicin and idarubicinol on blood progenitors in vitro and correlated findings with clinical outcomes in patients treated with high-dose idarubicin.
Participant Demographics
Patients with poor prognosis lymphoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website